Please login to the form below

Not currently logged in


This page shows the latest AML news and features for those working in and with pharma, biotech and healthcare.

Latest news

More from news
Approximately 14 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    population and taking the total number of new drugs for AML in the last couple of years to seven, after decades of stagnation. ... EvaluatePharma has predicted it could become a nearly $2.5bn product by 2024, providing it can also pick up approvals in

  • Digital disruption Digital disruption

    Initially AZ and Microsoft have focused acute myeloid leukaemia (AML), simulating experiments to predict how drug combinations might be used to overcome resistance to drugs that target cell signalling in AML,

  • Deal Watch December 2016 Deal Watch December 2016

    790. Tolero Pharma (US). Dainippon Sumitomo (Japan). Acquisition with milestones. Portfolio, including alvocidib, a CDK9 inhibitor with phase II completed in AML.

  • Deal Watch July 2016 Deal Watch July 2016

    Earlier this year Jazz completed its acquisition of Celator Pharmaceuticals, acquiring a late-stage product, Vyxeos, which targets AML, and the new agreement brings complementary products to Jazz's portfolio.

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $150m upfront Novartis gains access to XmAb14045 being developed for acute myeloid leukaemia (AML) and XmAb13676 in development for B-cell malignancies. ... 2 T-cell engaging XmAb bispecific antibodies: XmAb14045 for AML and XmAb13676 for B-cell

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Actinium appoints director of clinical operations Actinium appoints director of clinical operations

    Greg's direct experience in AML and significant knowledge of clinical trial management will have an immediate impact on our capabilities that we expect will add efficiency and scale to our

  • Celgene promotes Karen Browne to haematology director Celgene promotes Karen Browne to haematology director

    She then relocated to Switzerland in March 2010, taking up the role of associate director of MDS and acute myeloid leukaemia (AML), and less than two years later was promoted to ... director with responsibility for overall MDS/AML marketing across Europe.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....